|Bid||13.50 x 1200|
|Ask||16.00 x 1000|
|Day's range||13.80 - 14.70|
|52-week range||11.75 - 23.64|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Every investor in Spero Therapeutics, Inc. ( NASDAQ:SPRO ) should be aware of the most powerful shareholder groups...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.